Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -95.00% | -99.92% |
Apr. 12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
Mar. 08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
Financials (USD)
Sales 2021 | 3.6 | Sales 2022 | 2.51 | Capitalization | 14.29M |
---|---|---|---|---|---|
Net income 2021 | -237M | Net income 2022 | -70M | EV / Sales 2021 | 53,517,059 x |
Net cash position 2021 | 45.01M | Net cash position 2022 | 10.16M | EV / Sales 2022 | 1,644,636 x |
P/E ratio 2021 |
-0.92
x | P/E ratio 2022 |
-0.15
x | Employees | 6 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.65% |
1 day | -99.00% | ||
Current month | -99.50% | ||
3 months | -99.75% | ||
6 months | -99.67% | ||
Current year | -99.92% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 16-01-06 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-07-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 16-01-06 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-07-05 |
Ronald Barliant
BRD | Director/Board Member | 78 | 16-01-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 0.000001 | -99.00% | 7,883 |
24-05-14 | 0.0001 | +9,900.00% | 8,479 |
24-05-13 | 0.000001 | -99.50% | 505 |
24-05-10 | 0.0002 | 0.00% | 2,418 |
24-05-09 | 0.0002 | +900.00% | 35,001 |
Delayed Quote OTC Markets, May 15, 2024 at 09:33 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-99.92% | 119 | |
-0.07% | 91.42B | |
+2.76% | 41.08B | |
-9.06% | 34.26B | |
+55.32% | 25.27B | |
-16.61% | 15.27B | |
-9.14% | 12.81B | |
-12.11% | 11.6B | |
-43.61% | 11.42B | |
+7.79% | 9.16B |
- Stock Market
- Equities
- HGENQ Stock